Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967629 · ClinicalTrials.gov registry record · Phase 1
Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
A Phase 1 study of Diabetic Nephropathy, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00967629 is a Phase 1 study of Diabetic Nephropathy that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00967629, a Phase 1 study of Diabetic Nephropathy, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephropathy leading to decrease body AGE load and therefore decreases the inflammation and oxidative stress in these patients.
Conditions Studied
Interventions
- DRUG Calcium Carbonate
- DRUG Sevelamer Carbonate
Study Locations (1)
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967629
The ClinicalTrials.gov registry entry for NCT00967629 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Calcium Carbonate is the first listed.
NCT00967629 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00967629 about?
NCT00967629 is a clinical study titled "Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy". The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephropathy leading to decrease body AGE load and therefore decreases the inflammation and oxidative stress in these pa...
What is the current status of trial NCT00967629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-06. Estimated completion is 2010-02.
What conditions does trial NCT00967629 study?
This clinical trial studies the following conditions: Diabetic Nephropathy.
What interventions are being tested in trial NCT00967629?
The interventions under investigation include: Calcium Carbonate (DRUG), Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT00967629?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00967629 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
COMPLETED · NA
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.